William Blair analyst Sami Corwin has reiterated their neutral stance on SRPT stock, giving a Hold rating on August 4.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Sami Corwin has given his Hold rating due to a combination of factors, primarily revolving around Sarepta Therapeutics’ recent financial performance and clinical trial developments. The company’s second-quarter earnings showed a revenue beat, largely attributed to a milestone payment from Roche, which contributed to a total product revenue of $611 million. However, despite this positive financial outcome, the updated 2025 revenue outlook was not provided, leaving some uncertainty about the company’s future financial trajectory.
Additionally, while the Phase I Study-104 demonstrated proof-of-concept for AAV nAb depletion, the efficacy of the treatment remains questionable. The trial showed that patients could achieve low anti-AAV titer levels, allowing for Elevidys treatment, but the expression of micro-dystrophin was lower than in other trials. Furthermore, Sarepta’s ongoing trials in FSHD1, DM1, and SCA2 have reached full enrollment, yet the outcomes and next steps remain to be clarified. These mixed signals from both financial and clinical perspectives contribute to the Hold rating, as the potential for growth is balanced by uncertainties.
According to TipRanks, Corwin is a 3-star analyst with an average return of 3.2% and a 44.33% success rate. Corwin covers the Healthcare sector, focusing on stocks such as Sarepta Therapeutics, Crispr Therapeutics AG, and Ultragenyx Pharmaceutical.
In another report released on August 4, RBC Capital also maintained a Hold rating on the stock with a $14.00 price target.